Media Articles Related to Optison (Albumin Human)
New Considerations in HIV Care Diagnostics
Source: Medscape HIV/AIDS Headlines [2015.01.20]
Dr Benjamin Young highlights the recently announced UNAIDS Fast-track Cities program and reviews two new studies on HIV diagnostics.
Sepsis diagnostic quickly IDs most lethal form of sepsis
Source: Blood / Hematology News From Medical News Today [2015.01.15]
T2 Biosystems, a company developing innovative diagnostic products to improve patient health, today announced that results from its pivotal trial evaluating its lead products, the T2Candida Panel...
New diagnostic test for bowel diseases
Source: Irritable-Bowel Syndrome News From Medical News Today [2014.03.31]
A novel method for distinguishing different types of bowel disease using the stool samples of patients has been created by a group of researchers in the UK.
Heart attack diagnoses 'could be doubled' by gender-specific tests
Source: Cardiovascular / Cardiology News From Medical News Today [2015.01.22]
Researchers find that using a new high-sensitivity blood test with gender-specific diagnostic thresholds could improve the rate of heart attack diagnosis among women.
VolitionRX begins first ovarian cancer detection study to evaluate blood-based test
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.01.22]
VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, has announced it has signed an agreement to...
Published Studies Related to Optison (Albumin Human)
Effects of combined lipoic acid and pyridoxine on albuminuria, advanced glycation
end-products, and blood pressure in diabetic nephropathy. 
This study was designed to investigate the effects of combined administration of
lipoic acid and pyridoxine on albuminuria, oxidative stress, blood pressure,
serum advanced glycation end-products, nitric oxide (NO), and endothelin-1 in
patients with diabetic nephropathy.
High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a
randomised, double-blind, phase 3, placebo-controlled trial. 
proportion of patients with a favourable outcome... INTERPRETATION: Our findings show no clinical benefit of 25% albumin in patients
Albumin resuscitation for traumatic brain injury: is intracranial hypertension
the cause of increased mortality? 
Mortality is higher in patients with traumatic brain injury (TBI) resuscitated
with albumin compared with saline, but the mechanism for increased mortality is
Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. [2011.07]
CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatinine ratio is independently associated with HbA1c and NT-proBNP, even in non-diabetic patients.
Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria:Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). [2011.06]
BACKGROUND: The PREVEND IT investigated whether treatment targeted at lowering urinary albumin excretion (UAE) would reduce adverse cardiovascular events. We obtained extended follow-up data to approximately 10 years to investigate the long-term effects of fosinopril 20 mg and pravastatin 40 mg on cardiovascular outcomes in subjects with UAE >15 mg per 24 hours... CONCLUSIONS: Elevated UAE is associated with increased cardiovascular mortality and morbidity after 9.5 years of follow-up, with a doubling of the risk if the UAE is >50 mg per 24 hours. In this group, the benefits of 4-year treatment with fosinopril were sustained during posttrial follow-up for cardiovascular mortality and morbidity. We propose that UAE be used to estimate risk in the general population and that large clinical trials be designed to confirm the hypothesis that angiotensin-converting enzyme-inhibitor treatment may be beneficial in patients with mildly elevated UAE despite the absence of other comorbidities. Copyright (c) 2011 Mosby, Inc. All rights reserved.
Clinical Trials Related to Optison (Albumin Human)
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure and Pulmonary Vascular Resistance [Recruiting]
Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors [Suspended]
St. Jude Children's Research Hospital is studying ways to make ultrasound images clearer - to
be able to see blood vessels, body structures, and tumors better. Ultrasound uses sound waves
to create pictures, allowing doctors and other medical professionals to "see" inside the
Researchers are studying a contrast agent (like a dye) called Optison™. St. Jude Children's
Research Hospital researchers want to learn the best and safest dose of this ultrasound
Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease [Recruiting]
The purpose of this study is to find the optimal dose from 3 different dose levels - 0. 15
mL, 0. 5 mL and 1. 5 mL of Optison in assessing the presence of disease of the carotid
arteries when comparing pre-contrast to post-contrast ultrasound (U/S) by dose group.
A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice. [Recruiting]
This prospective surveillance trial will gather safety information for Optison when it is
used in routine practice.
CeVUS With Intravesical Administration of OPTISON TM (Trademark) in Children [Recruiting]
In this clinical trial the investigators aim to evaluate the diagnostic feasibility and
safety of ceVUS with the intravesical use of OPTISON for vesicoureteral reflux detection and
urethral imaging in children.